摘要
为制备P210/MMC、P210/TNP及P40/CD3三种双特异性抗体(BsAb),采用不同技术路线进行细胞融合11次,接种7,484孔,生长1,111孔,双阳性孔为223,但仅获分泌BsAb的2次杂交瘤5株,可见BsAb的制备殊非易事.桥联法在确认BsAb的分泌性状时有重要意义,12株分泌γ及μ两种重链的三体杂交瘤,仅2株分泌BsAb,因此γ与μ形成组合的机率为16.7(2/12).BsAb(P210/TNP)带有“通用接头”,可介导多种TNP化的药物或毒素对胃癌靶细胞的杀伤效应.BsAb(P40/CD3)可介导外周血淋巴细胞(PBLs)对胃癌的杀伤效应,采用局部注射,4次治疗可使移植胃癌全部消退,对临床试用有参考价值.
Bi-specific antibodies (BsAb) P210/MMC, P210/TNP and P40/CD3 were prepared with different approaches. Among 11 fusions, 7, 484 wells were planted, and 223 dual positive wells were obtained from 1, 111 growth wells, only five hybrid-hybridomas secreting BsAb were obtained, showing the difficulties to prepare BsAb. It was shown that bridge assay is very important for identification of the BsAb. Among 12 triomas secreting y and μ chains, only two had BsAb. Therefore, the frequency for y and μ to combine to BsAb was 16.7(2/12). BsAb(P210/TNP) with versatile adaptor could mediate cytotoxic effects on target cells of different cytotoxic agents conjugated with TNP.Moreover, BsAb(P40/CD3) could mediate cytotoxic effects of peripheral blood lymphocytes (PBLs) on target cells. With local injection, four times treatments could abolish the tumor xenografts in nude mice.
出处
《中国肿瘤生物治疗杂志》
CAS
CSCD
1995年第2期99-103,共5页
Chinese Journal of Cancer Biotherapy
